Establishment of a novel survival assessment and prediction model for advanced gastric cancer patients receiving immunotherapy

Sun,Mingmin; Yang,Yang; Zhao,Jun

doi:10.3892/ol.2023.14038

Establishment of a novel survival assessment and prediction model for advanced gastric cancer patients receiving immunotherapy

Authors:
- Mingmin Sun
- Yang Yang
- Jun Zhao
View Affiliations

Affiliations: Department of Epidemiology and Statistics, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, P.R. China, Department of Oncology, Gulou Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China, Academician Workstation, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China
Published online on: August 31, 2023 https://doi.org/10.3892/ol.2023.14038
Article Number: 451
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Currently, there are only a few risk assessment tools that provide predictions of survival duration for patients with gastric cancer (GC) receiving immunotherapy. The purpose of the present study was to develop and validate a nomogram that uses statistical data to predict survival and make risk assessments for patients with advanced staged GC. A total of 1,013 patients consisting of a development cohort (n=501) and validation cohort (n=512) collected during the time interval between January 2018 and June 2022 were included in the present study. The analysis consisted of the discrimination index, calibration plots and decision curve of the nomogram model. A total of 167 (33.33%) patients from the development cohort, and 158 (30.85%) from the validation cohort died during the observation period. The median overall survival (OS) of female patients was higher at 980 days (95% CI, 613‑NA) compared with that of male patients, which was 748 days (95% CI, 597‑NA; P=0.24). The median survival of patients with domestic immunotherapy was 789 (95% CI, 597‑NA) days, which was lower compared with the imported immunotherapy group who had a median OS of 980 days (95% CI, 582‑NA; P=0.22). A total of four independent predictors, age (HR=1.012; P=0.0245), histological grade (HR=1.395; P=0.016), immunotherapy cycles (HR=0.932; P=0.028) and line of first immunotherapy (HR=1.693; P=0.0003), were identified. The C‑index was 0.64 and 0.67 for the development and validation cohorts, respectively. Patients who received more cycles of immunotherapy as the first‑line treatment with highly differentiated tumor led to increase in the survival time of the patients. Thus, this nomogram could be used to determine the benefit of immunotherapies on patients at various stages of treatment of GC.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide forb36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
3	Nicholls RJ, Zinicola R and Haboubi N: Extramural Spread of rectal cancer and the AJCC Cancer Staging Manual 8thedition, 2017. J Ann Oncol. 30:1394–1395. 2019. View Article : Google Scholar : PubMed/NCBI
4	Japanese Gastric Cancer Association, . Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 20:1–19. 2017. View Article : Google Scholar
5	Lordick F, Mariette C, Haustermans K, Obermannová R and Arnold D; ESMO Guidelines Committee, : Oesophageal cancer: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 27:50–57. 2016. View Article : Google Scholar
6	Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N and Schlemper RJ: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 345:784–793. 2001. View Article : Google Scholar : PubMed/NCBI
7	Lu J, Xu BB, Zheng CH, Li P, Xie JW, Wang JB, Lin JX, Chen QY, Truty MJ and Huang CM: Development and external validation of a nomogram to predict recurrence free survival after Ro resection for Stage II/III gastric cancer: An International Multicenter Stud. Front Oncol. 10:5746112020. View Article : Google Scholar : PubMed/NCBI
8	Song Z, Wu Y, Yang J, Yang D and Fang X: Progress in the treatment of advanced gastric cancer. Tumour Biol. 39:10104283177146262017. View Article : Google Scholar : PubMed/NCBI
9	Edge SB, Byrd DR, Carducci MA, Greene FL and Trotti A: AJCC Cancer Staging Manual. pp. 649Springer; New York: 2010
10	Wang FH, Zhang XT, Li YF, Tang L, Qu XJ, Ying JE, Zhang J, Sun LY, Lin RB, Qiu H, et al: The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun (Lond). 41:747–795. 2021. View Article : Google Scholar : PubMed/NCBI
11	Bang YJ, Ruiz EY, Van Cutsem E, Lee KW, Wyrwicz L, Schenker M, Alsina M, Ryu MH, Chung HC, Evesque L, et al: Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: Primary analysis of JAVELIN Gastric 300. Ann Oncol. 29:2052–2060. 2018. View Article : Google Scholar : PubMed/NCBI
12	Song Y, Fu Y, Xie Q, Zhu B, Wang J and Zhang B: Anti-angiogenic agents in combination with immune checkpoint inhibitors: A promising strategy for cancer treatment. Front Immunol. 11:19562020. View Article : Google Scholar : PubMed/NCBI
13	Hack SP, Zhu AX and Wang Y: Augmenting anticancer immunity through combined targeting of angiogenic and PD-1/PD-L1 pathways: Challenges and opportunities. Front Immunol. 11:5988772020. View Article : Google Scholar : PubMed/NCBI
14	Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, et al: First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. Lancet. 398:27–40. 2021. View Article : Google Scholar : PubMed/NCBI
15	Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglevic C, Chung HC, et al: Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): A randomised, open-label, controlled, phase 3 trial. Lancet. 392:123–133. 2018. View Article : Google Scholar : PubMed/NCBI
16	Kattan MW, Karpeh MS, Mazumdar M and Brennan MF: Postoperative nomogram for disease-specific survival after an Ro resection for gastric carcinoma. J Clin Oncol. 21:3647–3650. 2003. View Article : Google Scholar : PubMed/NCBI
17	Song KY, Park YG, Jeon HM and Park CH: A nomogram for predicting individual survival of patients with gastric cancer who underwent radical surgery with extended lymph node dissection. Gastric Cancer. 17:287–293. 2014. View Article : Google Scholar : PubMed/NCBI
18	Lacy PD, Piccirillo JF, Merritt MG and Zequeira MR: Head and neck squamous cell carcinoma: Better to be young. Otolaryngol Head Neck Surg. 122:253–258. 2000. View Article : Google Scholar : PubMed/NCBI
19	Bollschweiler E, Plum P, Mönig SP and Hölscher AH: Current and future treatment options for esophageal cancer in the elderly. Expert Opin Pharmacother. 18:1001–1010. 2017. View Article : Google Scholar : PubMed/NCBI
20	Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL and Siegel RL: Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 69:363–385. 2019. View Article : Google Scholar : PubMed/NCBI
21	Shariat SF, Sfakianos JP, Droller MJ, Karakiewicz PI, Meryn S and Bochner BH: The effect of age and gender on bladder cancer: A critical review of the literature. BJU Int. 105:300–308. 2010. View Article : Google Scholar : PubMed/NCBI
22	Nicholls RJ, Zinicola R and Haboubi N: Extramural spread of rectal cancer and the AJCC Cancer Staging Manual 8th edition, 2017. J Ann Oncol. 30:1394–1395. 2019. View Article : Google Scholar : PubMed/NCBI
23	Bacigalupo R, Cudd P, Littlewood C, Bissell P, Hawley MS and Buckley Woods H: Interventions employing mobile technology for overweight and obesity: An early systematic review of randomized controlled trials. Obes Rev. 14:279–2791. 2013. View Article : Google Scholar : PubMed/NCBI
24	Wainana SM, Karomo JN, Kyalo R and Mutai N: Using data mining techniques and R software to analyze crime data in Kenya. Int J Data Sci Analysis. 6:202020. View Article : Google Scholar
25	Eom BW, Ryu KW, Nam BH, Park Y, Lee HJ, Kim MC, Cho GS, Kim CY, Ryu SW, Shin DW, et al: Survival nomogram for curatively resected Korean gastric cancer patients: Multicenter retrospective analysis with external validation. PLoS One. 10:01196712015. View Article : Google Scholar
26	Han DS, Suh YS, Kong SH, Lee HJ, Choi Y, Aikou S, Sano T, Park BJ, Kim WH and Yang HK: Nomogram predicting long-term survival after d2 gastrectomy for gastric cancer. J Clin Oncol. 30:3834–3874. 2012. View Article : Google Scholar : PubMed/NCBI
27	Hou S, Xie X, Peng Q, Zhou G, Li L, Zhou H, Zhang G and Zhou T: Prognostic factor analysis and prognostic model of liver metastasis of gastric cancer based on SEER database. Chin J Gen Surg. 29:1212–1223. 2020.(In Chinese).
28	Shin HJ, Choi YO, Roh CK, Son SY, Hur H and Han SU: Prediction of survival outcomes based on preoperative clinical parameters in gastric cancer. Ann Surg Oncol. 28:7027–7037. 2021. View Article : Google Scholar : PubMed/NCBI